Helmholtz Gemeinschaft


The activity of titanocene T against xenografted Caki-1 tumors

Item Type:Article
Title:The activity of titanocene T against xenografted Caki-1 tumors
Creators Name:Walther, W. and Fichtner, I. and Deally, A. and Hogan, M. and Tacke, M.
Abstract:The indole-substituted titanocene dichloride derivative Titanocene T, which is completely water-soluble and shows micromolar activity against the human renal cancer cells Caki-1, was tested in vivo an against xenografted human renal cell tumors in mice. Titanocene T was then given at 25 and 50 mg/kg, seven times every four days during three weeks to two groups (n=6) of Caki-1 tumor-bearing female NMRI: nu/nu mice, while the control group was treated with solvent only. At both doses Titanocene T induced a moderate to good tumor growth reduction with respect to the solvent-treated control group, with an optimal T/C value of 51% and 32% and showed neither mortality nor toxicity. Immunohistochemical analysis revealed that the expression of the proliferation marker Ki-67 was reduced in the high-dosage group. Furthermore, anti-angiogenic activity was identified by CD31 staining; the number of micro vessels in a defined tumor area decreased by 27% and 29% due to Titanocene T treatment.
Keywords:Anticancer Drug, Anti-Angiogenic Drug, Titanocene, Renal Cell Cancer, Xenograft
Source:Letters in Drug Design & Discovery
Page Range:375-381
Date:June 2013
Official Publication:https://doi.org/10.2174/1570180811310050002

Repository Staff Only: item control page

Open Access
MDC Library